NR1I2 and neoplasm: In this event, treatment of patients with standard therapies together with SXR antagonists [28,75], or with SXR-transparent chemotherapeutic agents could prove beneficial both in blocking tumor growth and in improving the therapeutic efficacy of existing agents.